NCT01441882View on ClinicalTrials.gov

Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

July 12, 2016

Study Completion Date

January 1, 2018

Conditions

Refractory Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic LeukemiaStage IV Chronic Lymphocytic Leukemia

Interventions

DRUG

Dasatinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

All Listed Sponsors

collaborator

Oregon Health and Science University

OTHER

lead

OHSU Knight Cancer Institute

OTHER

NCT01441882 - Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter